Cancer cachexia contender enters first pivotal trial.
vol.24 iss.11 (2025) FDA approves BTK inhibitor for chronic hives.
vol.24 iss.11 (2025) Roche buys MASH contender for up to US$3.5 billion.
vol.24 iss.11 (2025) FDA new drug approvals in Q3 2025.
vol.24 iss.11 (2025) Innovation in medicines for global health: a 20-year landscape analysis.
vol.24 iss.11 (2025) Embracing the avoid-ome.
vol.24 iss.11 (2025) Designer peptide retunes channel function.
vol.24 iss.11 (2025) Macrocyclic peptides challenge cell cycle defects.
vol.24 iss.11 (2025) Epigenetic inhibitor silences KRAS-driven oncogenes.
vol.24 iss.10 (2025) Gut microbiota-derived metabolite drives atherosclerosis.
vol.24 iss.10 (2025) FDA approves first factor XIIa inhibitor, for hereditary angioedema.
vol.24 iss.8 (2025) A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) Stealthy polymer attacks Gram-negative bacteria.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy.
vol.24 iss.7 (2025) FDA approves l-amino acid decarboxylase deficiency gene therapy
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025) 2024 FDA approvals exceed average number but have lower sales projections.
(2025) Biopharma dealmaking in 2024.
(2025) Outlook for medicines development and use in 2025.
(2025) DLL3 draws two antibody-drug conjugate deals.
(2025) FDA approves next-generation triple therapy for cystic fibrosis.
(2025) Targeting inherited mutations to prevent metastasis.
(2025) Designing proteins targeting neosurfaces.
(2025) Degrading aurora kinase A in neuroblastoma.
(2025) The multiple myeloma drug market.
(2025) FDA approves new non-opioid pain drug.
(2025) A new European platform for advancing regulatory science research.
(2025) FDA approves TROP2-targeted antibody-drug conjugate for breast cancer.
(2025) Directing autophagy to degrade cell surface receptors.
(2025) Designer proteins take the bite out of snake venom.
(2025) Peptide blocks phase separation and oncogenic transcription.
(2025) New target to tackle coronaviruses.
(2025) PKC modulator promotes remyelination.
(2025) Approvals by the China NMPA in 2024.
(2025) Clinical development success rates for durable cell and gene therapies.
(2025) Genetics opens new route to degrader discovery.
(2025) Adrenomedullin triggers insulin resistance.
(2025) A platform for personalized ASO therapeutics.
(2025) Reversing lysosomal dysfunction to treat PAH.
(2025) Oral STING agonist inhibits tumour growth.
(2025)
vol.24 iss.11 (2025) FDA approves BTK inhibitor for chronic hives.
vol.24 iss.11 (2025) Roche buys MASH contender for up to US$3.5 billion.
vol.24 iss.11 (2025) FDA new drug approvals in Q3 2025.
vol.24 iss.11 (2025) Innovation in medicines for global health: a 20-year landscape analysis.
vol.24 iss.11 (2025) Embracing the avoid-ome.
vol.24 iss.11 (2025) Designer peptide retunes channel function.
vol.24 iss.11 (2025) Macrocyclic peptides challenge cell cycle defects.
vol.24 iss.11 (2025) Epigenetic inhibitor silences KRAS-driven oncogenes.
vol.24 iss.10 (2025) Gut microbiota-derived metabolite drives atherosclerosis.
vol.24 iss.10 (2025) FDA approves first factor XIIa inhibitor, for hereditary angioedema.
vol.24 iss.8 (2025) A neonatal window for in vivo gene therapy in haematopoietic stem cells.
vol.24 iss.8 (2025) Stealthy polymer attacks Gram-negative bacteria.
vol.24 iss.8 (2025) In utero ASO therapy for spinal muscular atrophy.
vol.24 iss.7 (2025) FDA approves l-amino acid decarboxylase deficiency gene therapy
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025) 2024 FDA approvals exceed average number but have lower sales projections.
(2025) Biopharma dealmaking in 2024.
(2025) Outlook for medicines development and use in 2025.
(2025) DLL3 draws two antibody-drug conjugate deals.
(2025) FDA approves next-generation triple therapy for cystic fibrosis.
(2025) Targeting inherited mutations to prevent metastasis.
(2025) Designing proteins targeting neosurfaces.
(2025) Degrading aurora kinase A in neuroblastoma.
(2025) The multiple myeloma drug market.
(2025) FDA approves new non-opioid pain drug.
(2025) A new European platform for advancing regulatory science research.
(2025) FDA approves TROP2-targeted antibody-drug conjugate for breast cancer.
(2025) Directing autophagy to degrade cell surface receptors.
(2025) Designer proteins take the bite out of snake venom.
(2025) Peptide blocks phase separation and oncogenic transcription.
(2025) New target to tackle coronaviruses.
(2025) PKC modulator promotes remyelination.
(2025) Approvals by the China NMPA in 2024.
(2025) Clinical development success rates for durable cell and gene therapies.
(2025) Genetics opens new route to degrader discovery.
(2025) Adrenomedullin triggers insulin resistance.
(2025) A platform for personalized ASO therapeutics.
(2025) Reversing lysosomal dysfunction to treat PAH.
(2025) Oral STING agonist inhibits tumour growth.
(2025)
